CA3065783A1 - Dosing schedule for tesetaxel and capecitabine - Google Patents

Dosing schedule for tesetaxel and capecitabine Download PDF

Info

Publication number
CA3065783A1
CA3065783A1 CA3065783A CA3065783A CA3065783A1 CA 3065783 A1 CA3065783 A1 CA 3065783A1 CA 3065783 A CA3065783 A CA 3065783A CA 3065783 A CA3065783 A CA 3065783A CA 3065783 A1 CA3065783 A1 CA 3065783A1
Authority
CA
Canada
Prior art keywords
capecitabine
day
administering
day cycle
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3065783A
Other languages
English (en)
French (fr)
Inventor
Thomas Wei
Kevin Tang
Stew Kroll
John G. Lemkey
Steven Pfeiffer
Jeff Vacirca
Original Assignee
Odonate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Odonate Therapeutics Inc filed Critical Odonate Therapeutics Inc
Publication of CA3065783A1 publication Critical patent/CA3065783A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3065783A 2017-06-02 2018-06-01 Dosing schedule for tesetaxel and capecitabine Abandoned CA3065783A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762514483P 2017-06-02 2017-06-02
US62/514,483 2017-06-02
PCT/US2018/035653 WO2018223029A1 (en) 2017-06-02 2018-06-01 Dosing schedule for tesetaxel and capecitabine

Publications (1)

Publication Number Publication Date
CA3065783A1 true CA3065783A1 (en) 2018-12-06

Family

ID=64455637

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3065783A Abandoned CA3065783A1 (en) 2017-06-02 2018-06-01 Dosing schedule for tesetaxel and capecitabine

Country Status (14)

Country Link
US (1) US20200179427A1 (https=)
EP (1) EP3630091A4 (https=)
JP (1) JP2020522568A (https=)
KR (1) KR20200014880A (https=)
CN (1) CN111032035A (https=)
AU (1) AU2018275122A1 (https=)
BR (1) BR112019025164A2 (https=)
CA (1) CA3065783A1 (https=)
EA (1) EA201992852A1 (https=)
IL (1) IL270973A (https=)
MA (1) MA50039A (https=)
MX (1) MX2019014489A (https=)
TW (1) TW201902473A (https=)
WO (1) WO2018223029A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53929A (fr) * 2018-10-17 2021-08-25 Odonate Therapeutics Inc Méthodes de traitement de tumeurs du système nerveux central au moyen de tesetaxel
WO2021034335A1 (en) * 2019-08-16 2021-02-25 Odonate Therapeutics, Inc. Methods of administering tesetaxel with glucocorticoids that are cyp3a4 inducers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168451A1 (en) * 2015-04-14 2016-10-20 Merrimack Pharmaceuticals, Inc. Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment

Also Published As

Publication number Publication date
AU2018275122A1 (en) 2019-12-19
EA201992852A1 (ru) 2020-03-27
TW201902473A (zh) 2019-01-16
KR20200014880A (ko) 2020-02-11
MA50039A (fr) 2020-07-08
WO2018223029A1 (en) 2018-12-06
IL270973A (en) 2020-01-30
US20200179427A1 (en) 2020-06-11
JP2020522568A (ja) 2020-07-30
CN111032035A (zh) 2020-04-17
EP3630091A4 (en) 2021-03-10
BR112019025164A2 (pt) 2020-06-16
EP3630091A1 (en) 2020-04-08
MX2019014489A (es) 2020-08-17

Similar Documents

Publication Publication Date Title
ES2228932T3 (es) Procedimiento de tratamiento del carcinoma positivo de estrogenos.
AU2013205648B2 (en) Combination treatment
US7834056B2 (en) Pharmaceutical composition for gout
EA030335B1 (ru) Применение амисульприда в качестве противорвотного средства
AU1217697A (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
WO2019067860A1 (en) COMPOSITIONS AND METHODS FOR MODULATION OF HAIR GROWTH
CA3065783A1 (en) Dosing schedule for tesetaxel and capecitabine
WO2021034335A1 (en) Methods of administering tesetaxel with glucocorticoids that are cyp3a4 inducers
ES2573295T3 (es) Combinaciones farmacéuticas que comprenden un inhibidor de Hsp90 derivado de isoxazol y el inhibidor de HER2 trastuzumab
ES2989170T3 (es) Métodos no hormonales para la anticoncepción masculina que comprenden (R)-silodosina
WO2022197293A1 (en) Methods of administering tesetaxel to patients with hepatic impairment
WO2024050145A1 (en) Thiostrepton dosing regimens
HK40029016A (en) Dosing schedule for tesetaxel and capecitabine
WO2022197290A1 (en) Methods of administering tesetaxel with cyp3a4 inhibitors
US20210386720A1 (en) Methods of treating cns tumors with tesetaxel
WO2011044105A1 (en) Treatment with cholinergic agonists
TW202114717A (zh) 含有對硼苯基丙胺酸之注射液劑
ES2425398T3 (es) Antagonistas de receptor de colecistocinina-1 (CCK1) en el tratamiento de trastornos gastrointestinales y relacionados
WO2022265984A1 (en) Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders
WO2026015820A1 (en) Methods of treating vexas
KR20250044649A (ko) X-ald 치료를 위한 갑상선 베타-작용제 투여 요법
JP6643978B2 (ja) 頭頚部がんの処置または予防において使用されるｐｉ３キナーゼ阻害剤とパクリタキセルの組合せ
JP2009108058A (ja) 抗リンパ腫組成物および方法
WO2009111555A1 (en) Combination treatment for bladder cancer comprisining valrubicin and trospium chloride
WO2001035946A2 (en) Intranasal administration of raloxifene and tamoxifen

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20231201